Cancer

SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET

NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a…

12 months ago

Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development

Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development (OXFORDSHIRE,…

12 months ago

Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference

SAN FRANCISCO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical…

12 months ago

Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO…

12 months ago

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

INTASYL Compound RXI-231: a promising approach to treatment of hyperpigmentationMarlborough, Massachusetts--(Newsfile Corp. - January 2, 2025) - Phio Pharmaceuticals Corp.…

12 months ago

HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

— HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative…

12 months ago

Defence Arranges Financing

Vancouver, British Columbia--(Newsfile Corp. - December 31, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or…

12 months ago

Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA

Hamilton, Bermuda, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Further proof of great versatility of Altamira’s platform for extrahepatic RNA deliveryCircular…

12 months ago

Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

MIAMI, FL, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

12 months ago